Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2025 Jul-Aug;77(4):290-302.
doi: 10.1016/j.ihj.2025.05.011. Epub 2025 May 27.

The effect of mavacamten on echocardiographic parameters, cardiac function and biomarkers in hypertrophic cardiomyopathy patients, a systematic review and meta-analysis

Zina Otmani  1 , Noura Abdrabou  2 , Hazem Ayman Elsayed  3 , Mazen Negmeldin Aly Yassin  4 , Mohamed Abouzid  5 , Mahmoud Diaa Hindawi  6 , Ayman K Awad  7
Affiliations
Meta-Analysis

The effect of mavacamten on echocardiographic parameters, cardiac function and biomarkers in hypertrophic cardiomyopathy patients, a systematic review and meta-analysis

Zina Otmani et al. Indian Heart J. 2025 Jul-Aug.

Abstract

Background: Evaluate the effect of mavacamten on echocardiographic parameters and cardiac biomarkers in patients with hypertrophic cardiomyopathy (HCM).

Methods: We searched PubMed, SCOPUS, Web of Science, and Cochrane Library until November 2023. Results were reported as mean difference (MD) and Risk Ratio (RR) with 95 % confidence intervals (CI).

Results: Seven studies with 524 patients (456 with obstructive HCM and 59 with non-obstructive HCM) were included. Mavacamten significantly improved septal early diastolic mitral annular velocity (e') (MD 0.78, 95 % CI [0.51 to 1.05]) and left ventricular mass index (LVMI). It reduced left ventricular outflow tract (LVOT) gradient, NT-proBNP (MD -557.14, 95 % CI [-685.59 to -428.68]), and troponin levels. Improvements were also seen in left atrial volume index (MD -6.26, 95 % CI [-8.88 to -3.63]) and E/e' ratios, particularly in obstructive HCM patients.

Conclusion: Mavacamten enhances echocardiographic and cardiac biomarker outcomes in HCM patients on short-term follow-up. Limited data on non-obstructive HCM require cautious interpretation.

Keywords: Beta-blockers; Cardiac myosin inhibitor; Hypertrophic cardiomyopathy; Mavacamten.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig. 1
Fig. 1
PRISMA chart of the reported studies showing the search selection strategy and exclusion criteria.
Fig. 2
Fig. 2
Forest plots for Left Ventricular Outflow Tract (LVOT) gradient A: post-exercise LVOT gradient B: Rest LVOT gradient C: Valsalva LVOT gradient.
Fig. 3
Fig. 3
Forest plots for diastolic function outcomes A- Left atrial volume index (LAVI) B: E/e' septal ratio C: E/e' lateral ratio D: Average E/e' E: Lateral Early diastolic mitral annular velocity (Lateral e') F: Septal Early diastolic mitral annular velocity (Septal e').
Fig. 3
Fig. 3
Forest plots for diastolic function outcomes A- Left atrial volume index (LAVI) B: E/e' septal ratio C: E/e' lateral ratio D: Average E/e' E: Lateral Early diastolic mitral annular velocity (Lateral e') F: Septal Early diastolic mitral annular velocity (Septal e').
Fig. 4
Fig. 4
Forest plots for left ventricular parameters A: Left ventricular ejection fraction (LVEF) B: Left ventricular mass index (LVMI) C: Left ventricular end-diastolic volume (LVEDV).
Fig. 5
Fig. 5
Forest plots for cardiac biomarkers A: N-terminal pro-B-type natriuretic peptide (NT-proBNP) B: troponin.
Fig. 6
Fig. 6
Forest plots for secondary analysis (with and without beta-blockers) for left ventricular outflow tract (LVOT). A: LVOT gradient B: Valsalva LVOT gradient C: post-exercise LVOT gradient.
Fig. 7
Fig. 7
Forest plots for secondary analysis, with and without beta-blockers for A: resting LVEF B: peak VO2 C: VE/VCO2 D: KCCQ OSS E: Improvement in NYHA Functional Class F: Forest plot for subgroup analysis of NT-proBNP.
Fig. 7
Fig. 7
Forest plots for secondary analysis, with and without beta-blockers for A: resting LVEF B: peak VO2 C: VE/VCO2 D: KCCQ OSS E: Improvement in NYHA Functional Class F: Forest plot for subgroup analysis of NT-proBNP.
See this image and copyright information in PMC

References

    1. Maron B.J. Clinical course and management of hypertrophic cardiomyopathy. Longo D.L., editor. N Engl J Med. 2018;379:655–668. - PubMed
    1. Marian A.J., Braunwald E. Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. Circ Res. 2017;121:749–770. - PMC - PubMed
    1. Wigle E.D., Silver M.D. Myocardial fiber disarray and ventricular septal hypertrophy in asymmetrical hypertrophy of the heart. Circulation (New York, N Y) 1978;58:398–402. - PubMed
    1. Ommen S.R., Mital S., Burke M.A., et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: executive summary: a report of the American college of Cardiology/American heart association joint committee on clinical practice guidelines. Circulation (New York, N Y) 2020;142:e533–e557. - PubMed
    1. Tesic M., Seferovic J., Trifunovic D., et al. N-terminal pro-brain natriuretic peptide is related with coronary flow velocity reserve and diastolic dysfunction in patients with asymmetric hypertrophic cardiomyopathy. J Cardiol. 2017;70:323–328. - PubMed

MeSH terms